Dapagliflozin Alliance Targets Surging Indian Diabetes Market
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.
You may also be interested in...
India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals
After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
Lilly Plans Raft Of India Launches After Trulicity Success
Lilly’s diabetes drug Trulicity is doing “very well” in India despite a relatively hefty price tag, and the major US company is now planning to ramp up its product launches in this key emerging market as it taps into the growing number of patients moving into higher income brackets.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.